Global expert panel issues first consensus roadmap for brentuximab vedotin nerve damage
Brentuximab vedotin has transformed the outlook for patients with CD30-positive lymphomas, but the antibody-drug conjugate carries a neurological price that ...
Brentuximab vedotin has transformed the outlook for patients with CD30-positive lymphomas, but the antibody-drug conjugate carries a neurological price that ...
A systematic review of 32 studies finds chronic pain affects between 8.6% and 67.1% of long-term cancer survivors, with neuropathic ...
A comprehensive review reveals that single-cell sequencing of the dorsal root ganglion shows neuropathic pain is not one disease but ...
In the realm of oncology, a persistent challenge has been the long-term neurotoxic consequences faced by patients undergoing chemotherapy. While ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.